Saturday 17 October 2026
Export MAZE’s income statement to Excel — free account
Maze Therapeutics, Inc.
MAZE Healthcare Biotechnology
Maze Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $167.5 million. In the quarter to June 2026, EPS grew 1.30% and free cash flow grew 50.2%, each against the same quarter a year earlier.
27.53
0.05
+0.18%
Follow MAZE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (37.35%) | (38.67%) | (598.95%) | (5,050.31%) |
+8 more TTM periods Free account |
|
| (31.99%) | (32.57%) | (41.12%) | (57.18%) | ||
ROIC |
(112.36%) | (297.61%) | (684.43%) | 0.00% | |
Return on Tangible Assets |
(33.24%) | (33.74%) | (39.47%) | (37.65%) | |
Average Days of Receivables |
— | 0.00 | — | — | |
Free Cash Flow per Share |
(1.81) | (2.27) | (2.62) | (2.36) | |
Free Cash Flow |
(106.84) | (122.12) | (112.73) | (108.03) | |
Capital Expenditures |
(0.30) | (0.59) | (0.79) | (1.36) | |
| Other line items | |||||
Cash ROIC |
(11.83%) | (16.66%) | (16.18%) | (14.15%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.80 | 0.99 | 0.85 | 0.76 | |
Depreciation/Fixed assets |
0.55 | 0.54 | 0.48 | 0.47 | |
Capex/Depreciation |
(0.13) | (0.23) | (0.33) | (0.52) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.81) | (2.25) | (2.60) | (2.33) | |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.03) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates